在现代最佳医疗时代,心肌再血管化对缺血性心力衰竭的作用
Ioana-Paula Blaj-Tunduc1, Ciprian Marcel Ioan Brisc1,2, Cristina Mihaela Brisc1,2
1Doctoral School of Biomedical Sciences, Faculty of Medicine and Pharmacy, University of Oradea, 410087 Oradea, Romania.
Medicina (Kaunas, Lithuania)
|August 28, 2025
概括
对缺血性心力衰竭和减少喷射率的重血管化策略进行了审查. 虽然冠状动脉旁路移植改善了预后,但在某些情况下,最优的医疗治疗可能比穿皮冠状动脉干预更好.
科学领域:
- 心脏病学
- 心血管外科
- 干预心脏病学
背景情况:
- 缺血性病因占心力衰竭的50%以上.
- 尽管取得了进展,但HFrEF仍然与显著的死亡率和发病率有关.
- 心肌再血管化是改善缺血性HFrEF功能和结果的常见治疗方法.
研究的目的:
- 对慢性缺血性HFrEF患者的复血管化进行评估.
- 分析重血管化对症状,左心室重塑和主要心脏不良事件 (MACE) 的影响.
- 讨论最佳治疗策略,包括再血管化与最佳医学治疗 (OMT).
主要方法:
- 重新血管化的对症状,左心室逆向重塑和MACE的影响分析.
- 在慢性全封闭 (PCI-CTO) 中评估完整的血管化和穿皮冠状动脉干预.
- 对不同类型的患者进行再血管化与OMT的辩论.
主要成果:
- 建议进行冠状动脉旁路移植 (CABG),以改善多血管性缺血性HFrEF的预后.
- 对于高风险患者,心脏组评估对于PCI和CABG之间的选择至关重要.
- REVIVED-BCIS2试验建议在缺血性心肌病中使用OMT而不是PCI.
- 在RCT中,PCI- CTO与OMT改善了心脏病和生活质量,但MACE没有受到显著影响.
结论:
- 在某些缺血性HFrEF患者的预后改善中,CABG仍然是主要的重血管化策略.
- 在考虑心脏团队的意见时,对高风险患者进行个性化治疗决定是必要的.
- 目前的证据表明,在某些缺血性心肌病病例中,OMT可能优于PCI,等待进一步研究.
更多相关视频
09:11Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix
Published on: September 22, 2014
12.1K
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
8.6K
相关概念视频
01:14Myocarditis III: Medical Management
15
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
15
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
01:29Cardiomyopathy V: Interprofessional Care
32
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
32
01:28Acute Coronary Syndrome IV: Interprofessional Care
26
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
26
01:27Coronary Artery Disease V: Interprofessional Care
30
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
30
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505